Active, not recruitingPhase 2NCT05218668

Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Woolsey Pharmaceuticals
Intervention
Fasudil (WP-0512)(drug)
Enrollment
40 enrolled
Eligibility
18-75 years · All sexes
Timeline
20212029

Study locations (12)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05218668 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials